Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
2024

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis

Sample size: 115 publication Evidence: high

Author Information

Author(s): Rodríguez-Jorge Fernando, Fernández-Velasco José Ignacio, Villarrubia Noelia, Gracia-Gil Julia, Fernández Eva, Meca-Lallana Virginia, Díaz-Pérez Carolina, Sainz de la Maza Susana, Pacheco Eva María, Quiroga Ana, Ramió-Torrentà Lluis, Martínez-Yélamos Sergio, Bau Laura, Monreal Enric, López-Real Ana, Rodero-Romero Alexander, Borrega Laura, Díaz Santiago, Eguía Pablo, Espiño Mercedes, Chico-García Juan Luis, Barrero Francisco Javier, Martínez-Ginés María Luisa, García-Domínguez José Manuel, De la Fuente Soraya, Moreno Irene, Sainz-Amo Raquel, Mañé-Martínez M. Alba, Caminero Ana, Castellanos-Pinedo Fernando, Gómez López Ana, Labiano-Fontcuberta Andrés, Ayuso Lucía, Abreu Rossana, Hernández Miguel Ángel, Meca-Lallana José, Martín-Aguilar Lorena, Muriel García Alfonso, Masjuan Jaime, Costa-Frossard Lucienne, Villar Luisa María

Primary Institution: Hospital Universitario Ramón y Cajal, Madrid, Spain

Hypothesis

The study aims to evaluate variations of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and to ascertain the value of both serum biomarkers in predicting response to treatment.

Conclusion

Ocrelizumab induced normalization of sNfL and sGFAP in the majority of NEDA-3 and inflammatory patients but did not cause changes in the PIRA group.

Supporting Evidence

  • 85 patients (73.9%) achieved NEDA-3 after a year on ocrelizumab.
  • 30 patients did not achieve NEDA: 20 (17.4%) because of inflammatory activity and 10 (8.7%) because of progression independent of relapse activity.
  • Patients with elevated sNfL z-scores at baseline exhibit a higher risk of experiencing a relapse.

Takeaway

This study looked at how two blood markers change in people with multiple sclerosis who are treated with a medicine called ocrelizumab. It found that most people showed improvement, but some did not.

Methodology

Multicenter prospective study including 115 RRMS patients initiating ocrelizumab treatment, with serum samples collected at baseline and every 3 months to measure sNfL and sGFAP levels using SIMOA technology.

Limitations

The study has a relatively limited number of patients and time of follow-up.

Participant Demographics

76 women (66.1%), diagnosed at the age of 41.6 ± 10.1 years.

Statistical Information

P-Value

p = 0.0003 for sNfL, p = 0.03 for sGFAP

Confidence Interval

95% CI 1.12–3.99

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1480676

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication